Home
>
US Stocks
>
Quanterix Corporation

Quanterix Corporation (QTRX)

$20.36

+0.22

(+1.09%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Quanterix Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 25.89M → 28.45M (in $), with an average increase of 9.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -35.06M → -6.10M (in $), with an average increase of 146.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 29.8% return, outperforming this stock by 7.7%

  • Vs SYK

    In the last 3 years, Stryker Corp. has given 38.5% return, outperforming this stock by 61.3%

Performance

  • $19.96
    $20.75
    $20.36
    downward going graph

    1.96%

    Downside

    Day's Volatility :3.81%

    Upside

    1.88%

    downward going graph
  • $6.31
    $23.44
    $20.36
    downward going graph

    69.01%

    Downside

    52 Weeks Volatility :73.08%

    Upside

    13.14%

    downward going graph

Returns

PeriodQuanterix CorporationSector (Health Care)Index (Russel 2000)
3 Months
49.82%
0.9%
-8.3%
6 Months
56.62%
-6.8%
-6.5%
1 Year
22.14%
0.4%
-6.1%
3 Years
-22.76%
28.3%
21.8%

Highlights

Market Capitalization
753.4M
Book Value
$9.55
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.17
Wall Street Target Price
22.75
Profit Margin
-81.06%
Operating Margin TTM
-59.7%
Return On Assets TTM
-8.36%
Return On Equity TTM
-21.6%
Revenue TTM
104.4M
Revenue Per Share TTM
2.81
Quarterly Revenue Growth YOY
-3.6999999999999997%
Gross Profit TTM
46.8M
EBITDA
-56.9M
Diluted Eps TTM
-2.17
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.33
EPS Estimate Next Year
-1.38
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
-0.39

Analyst Recommendation

Hold
    0
    0%Buy
    66%Hold
    33%Sell
Based on 9 Wall street analysts offering stock ratings for Quanterix Corporation(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
6
6
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 11.74%

Current $20.36
Target $22.75

Company Financials

FY17Y/Y Change
Revenue
22.9M
↑ 30.08%
Net Income
-27.0M
↑ 16.6%
Net Profit Margin
-118.12%
↑ 13.66%
FY18Y/Y Change
Revenue
37.6M
↑ 64.52%
Net Income
-31.5M
↑ 16.72%
Net Profit Margin
-83.8%
↑ 34.32%
FY19Y/Y Change
Revenue
56.7M
↑ 50.76%
Net Income
-40.8M
↑ 29.36%
Net Profit Margin
-71.91%
↑ 11.89%
FY20Y/Y Change
Revenue
86.4M
↑ 52.25%
Net Income
-31.5M
↓ 22.71%
Net Profit Margin
-36.5%
↑ 35.41%
FY21Y/Y Change
Revenue
110.6M
↑ 27.99%
Net Income
-57.7M
↑ 82.96%
Net Profit Margin
-52.18%
↓ 15.68%
FY22Y/Y Change
Revenue
105.5M
↓ 4.55%
Net Income
-96.7M
↑ 67.63%
Net Profit Margin
-91.64%
↓ 39.46%
Q4 FY21Q/Q Change
Revenue
31.3M
↑ 17.3%
Net Income
-20.0M
↑ 27.87%
Net Profit Margin
-63.99%
↓ 5.29%
Q1 FY22Q/Q Change
Revenue
29.6M
↓ 5.57%
Net Income
-18.2M
↓ 9.35%
Net Profit Margin
-61.43%
↑ 2.56%
Q2 FY22Q/Q Change
Revenue
23.4M
↓ 20.73%
Net Income
-24.9M
↑ 37.18%
Net Profit Margin
-106.31%
↓ 44.88%
Q3 FY22Q/Q Change
Revenue
26.6M
↑ 13.75%
Net Income
-35.1M
↑ 40.81%
Net Profit Margin
-131.59%
↓ 25.28%
Q4 FY22Q/Q Change
Revenue
25.9M
↓ 2.8%
Net Income
-18.6M
↓ 47.01%
Net Profit Margin
-71.74%
↑ 59.85%
Q1 FY23Q/Q Change
Revenue
28.5M
↑ 9.87%
Net Income
-6.1M
↓ 67.15%
Net Profit Margin
-21.45%
↑ 50.29%
FY17Y/Y Change
Total Assets
91.8M
↑ 147.27%
Total Liabilities
25.9M
↑ 9.61%
FY18Y/Y Change
Total Assets
67.6M
↓ 26.33%
Total Liabilities
26.5M
↑ 2.44%
FY19Y/Y Change
Total Assets
170.0M
↑ 151.37%
Total Liabilities
41.3M
↑ 55.55%
FY20Y/Y Change
Total Assets
271.0M
↑ 59.48%
Total Liabilities
64.9M
↑ 57.22%
FY21Y/Y Change
Total Assets
501.5M
↑ 85.03%
Total Liabilities
60.6M
↓ 6.69%
FY22Y/Y Change
Total Assets
434.2M
↓ 13.42%
Total Liabilities
75.3M
↑ 24.24%
Q4 FY21Q/Q Change
Total Assets
501.5M
↓ 1.82%
Total Liabilities
60.6M
↑ 9.49%
Q1 FY22Q/Q Change
Total Assets
504.7M
↑ 0.62%
Total Liabilities
78.2M
↑ 29.18%
Q2 FY22Q/Q Change
Total Assets
488.6M
↓ 3.18%
Total Liabilities
83.1M
↑ 6.26%
Q3 FY22Q/Q Change
Total Assets
446.7M
↓ 8.58%
Total Liabilities
73.9M
↓ 11.09%
Q4 FY22Q/Q Change
Total Assets
434.2M
↓ 2.8%
Total Liabilities
75.3M
↑ 1.8%
Q1 FY23Q/Q Change
Total Assets
427.3M
↓ 1.59%
Total Liabilities
70.0M
↓ 7.01%
FY17Y/Y Change
Operating Cash Flow
-22.1M
↑ 24.6%
Investing Cash Flow
-1.1M
↑ 37.05%
Financing Cash Flow
73.2M
↑ 59.53%
FY18Y/Y Change
Operating Cash Flow
-28.7M
↑ 29.92%
Investing Cash Flow
-5.5M
↑ 381.8%
Financing Cash Flow
-78.0K
↓ 100.11%
FY19Y/Y Change
Operating Cash Flow
-26.2M
↓ 8.82%
Investing Cash Flow
-25.4M
↑ 365.27%
Financing Cash Flow
116.2M
↓ 149070.51%
FY20Y/Y Change
Operating Cash Flow
-23.4M
↓ 10.78%
Investing Cash Flow
-626.0K
↓ 97.53%
Financing Cash Flow
96.2M
↓ 17.18%
FY21Y/Y Change
Operating Cash Flow
-47.9M
↑ 105.04%
Investing Cash Flow
-6.3M
↑ 912.46%
Financing Cash Flow
270.8M
↑ 181.39%
FY22Y/Y Change
Operating Cash Flow
-48.3M
↑ 0.76%
Investing Cash Flow
-11.2M
↑ 76.81%
Financing Cash Flow
2.3M
↓ 99.15%
Q4 FY21Q/Q Change
Operating Cash Flow
-10.3M
↓ 25.3%
Investing Cash Flow
-2.2M
↑ 8.88%
Financing Cash Flow
-851.0K
↓ 79.04%
Q1 FY22Q/Q Change
Operating Cash Flow
-21.7M
↑ 110.79%
Investing Cash Flow
-874.0K
↓ 60.16%
Financing Cash Flow
979.0K
↓ 215.04%
Q2 FY22Q/Q Change
Operating Cash Flow
-7.9M
↓ 63.4%
Investing Cash Flow
-5.1M
↑ 478.95%
Financing Cash Flow
211.0K
↓ 78.45%
Q3 FY22Q/Q Change
Operating Cash Flow
-36.2M
↑ 356.45%
Investing Cash Flow
-3.7M
↓ 27.33%
Financing Cash Flow
1.4M
↑ 556.87%
Q4 FY22Q/Q Change
Operating Cash Flow
17.6M
↓ 148.58%
Investing Cash Flow
-1.6M
↓ 56.62%
Financing Cash Flow
-265.0K
↓ 119.12%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.5M
↓ 153.97%
Investing Cash Flow
-136.0K
↓ 91.47%
Financing Cash Flow
551.0K
↓ 307.92%

Technicals Summary

Sell

Neutral

Buy

Quanterix Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quanterix Corporation
Quanterix Corporation
10.71%
56.62%
22.14%
-22.76%
8.53%
Stryker Corporation
Stryker Corporation
-2.22%
16.98%
21.98%
40.5%
57.79%
Boston Scientific Corp.
Boston Scientific Corp.
-0.23%
14.09%
31.59%
38.48%
69.35%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.91%
15.56%
-11.48%
20.2%
79.31%
Abbott Laboratories
Abbott Laboratories
-6.01%
-1.15%
-10.5%
18.07%
65.34%
Medtronic PLC
Medtronic PLC
-6.17%
6.31%
-12.28%
-13.64%
-4.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quanterix Corporation
Quanterix Corporation
NA
NA
NA
-1.33
-0.22
-0.08
0.0
9.55
Stryker Corporation
Stryker Corporation
31.53
31.53
2.85
10.16
16.45
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
85.83
85.83
2.53
1.95
0.05
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
34.98
34.98
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
24.98
24.98
18.76
4.4
16.03
0.06
0.02
21.28
Medtronic PLC
Medtronic PLC
18.03
18.03
3.04
5.28
7.81
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quanterix Corporation
Quanterix Corporation
Hold
$753.4M
8.53%
NA
-81.06%
Stryker Corporation
Stryker Corporation
Buy
$104.6B
57.79%
31.53
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$74.0B
69.35%
85.83
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.7B
79.31%
34.98
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$178.8B
65.34%
24.98
13.98%
Medtronic PLC
Medtronic PLC
Buy
$110.1B
-4.3%
18.03
12.03%

Institutional Holdings

  • Camber Capital Management LLC

    9.16%

  • BlackRock Inc

    7.38%

  • Vanguard Group Inc

    4.96%

  • Millennium Management LLC

    4.40%

  • Frontier Capital Management CO Inc

    4.14%

  • Granahan Investment Management Inc..

    3.37%

Corporate Announcements

  • Quanterix Corporation Earnings

    Quanterix Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Organization
Quanterix Corporation
Employees
370
CEO
Dr. Masoud Toloue Ph.D.
Industry
Health Technology

Discover More

FAQs